SeekingAlpha · Sep 9, 2026
VO
NASDAQ · VOR
Vor Biopharma Inc.
Healthcare · Biotechnology
$23.24
Down-$0.90 (-3.85%)
Updated Sep 10, 2026, 10:14 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 83.27M
- P/E ratio
- -0.03
- Dividend yield
- 0.00%
- 52-week range
- $6.50 – $49.95
- Volume
- 824.97K
- Avg. volume
- 1.34M
Price performance
VOR price history
1M range · 20 trading sessions · Daily adjusted prices
VOR closed at $23.24 after 20 trading sessions, up 4.01% for the selected period.
- Last close
- $23.24
- Period change
- +4.01%
- Period low
- $22.34
- Period high
- $25.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $24.47 | $24.60 | $23.21 | $23.235 | 824.97K |
| Sep 8, 2026 | $24.75 | $26.00 | $24.10 | $25.10 | 856.98K |
| Sep 4, 2026 | $24.17 | $25.17 | $24.00 | $25.05 | 421.76K |
| Sep 3, 2026 | $24.80 | $24.94 | $23.88 | $24.24 | 538.76K |
| Sep 2, 2026 | $22.765 | $24.88 | $22.67 | $24.76 | 824.99K |
| Sep 1, 2026 | $22.32 | $22.88 | $22.0509 | $22.64 | 607.34K |
| Aug 31, 2026 | $22.50 | $22.76 | $22.28 | $22.48 | 847.99K |
| Aug 28, 2026 | $23.20 | $23.29 | $22.3792 | $22.65 | 491.05K |
| Aug 27, 2026 | $23.62 | $23.985 | $23.14 | $23.53 | 622.13K |
| Aug 26, 2026 | $23.68 | $24.09 | $23.39 | $23.67 | 448.01K |
| Aug 25, 2026 | $23.02 | $24.45 | $23.02 | $24.01 | 1.22M |
| Aug 24, 2026 | $23.12 | $23.175 | $21.90 | $22.71 | 500K |
| Aug 21, 2026 | $23.58 | $23.86 | $23.07 | $23.36 | 618.16K |
| Aug 20, 2026 | $23.05 | $23.405 | $22.79 | $23.065 | 649.62K |
| Aug 19, 2026 | $24.05 | $24.54 | $23.56 | $23.58 | 1.04M |
| Aug 18, 2026 | $22.82 | $23.845 | $22.62 | $23.28 | 1.01M |
| Aug 17, 2026 | $22.91 | $23.135 | $22.40 | $23.01 | 791.08K |
| Aug 14, 2026 | $23.33 | $23.35 | $22.38 | $23.03 | 417.57K |
| Aug 13, 2026 | $22.01 | $23.57 | $21.80 | $23.29 | 933.74K |
| Aug 12, 2026 | $23.48 | $23.51 | $21.75 | $22.34 | 992.2K |
Latest VOR news
The latest Smart Investors Daily articles mentioning VOR.
Stock researchCompany · Overview
VOR research
Overview
Company profile and research snapshot.
Company profile
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $58.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Wedbush | Neutral | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | Wedbush | Neutral | — |
| Apr 15, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2026 | Wedbush | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
Topline results from UPSTREAM MG’s 24-week primary endpoint remain on track for first half of 2027 Global Phase 3 ocular myasthenia gravis (oMG) registrational trial, UPSTREAM oMG, broadens telitacicept development across the myasthenia gravis (MG) spectrum; first patient dosing anticipated in the first half of 2027 BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the comple
Yahoo · Sep 1, 2026
Vor Bio To Participate in Upcoming September Conferences
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Forum: Fireside Chat and 1x1 Meetings Date: Tuesday, September 8th Presentation Time: 8:00AM ET Citi’s 2026 Biopharma Back to School Conference Forum: Fireside Chat and 1x1 Meetings Date: Wednesday, September 9
Benzinga · Aug 12, 2026
Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $18 to $27.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
